Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Cyclocytidine is a prodrug form of cytarabine (Item No. 16069) that is hydrolyzed to cytarabine in vivo.1 It inhibits the growth of L5178Y leukemia cells in vitro (IC50 = 0.041 µg/ml) and inhibits DNA synthesis by inhibiting thymidine incorporation into DNA (IC50 = 110 µg/ml).2 It increases lifespan in an L1210 mouse model of leukemia when administered at doses ranging from 3 to 1,000 mg/kg per day.1 Cyclocytidine transiently increases blood pressure in dogs, cats, and rats when administered at doses ranging from 5 to 100 mg/kg and induces postural hypotension in dogs, an effect that can be blocked by the α-adrenergic receptor antagonist phentolamine (Item No. 16135).3
WARNING This product is not for human or veterinary use.
1. 2,2'-
2. Inhibition by cyclocytidine of nucleic acid biosynthesis in cultured cells (L5178Y). Chem. Pharm. Bull. (Tokyo) 21(7), 1446-1450 (1973).
3. Mechanism of the cardiovascular actions of cyclocytidine. Proc. Soc. Exp. Biol. Med. 159(3), 374-379 (1978).